Business
SAB Biotherapeutics Awarded Additional $60.5M from BARDA and U.S. Department of Defense for Rapid Response Capability and Advancing SAB-185 for Treatment of COVID-19
$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response Expanded contract scope
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"\n$200 million total awarded to date for DiversitAb™ Rapid Response Antibody Program including Stage 4 COVID-19 Pandemic Response\n\nExpanded contract scope includes commercial manufacturing and clinical development through licensure for SAB-185 for the treatment of COVID-19\n\n SIOUX FALLS, S.D.--(BUSINESS WIRE)--\nSAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that the U.S. Department of Defense (DoD) has awarded the company an additional $60.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program for advanced clinical development through licensure and commercial manufacturing for SAB-185, the company’s therapeutic candidate for the treatment of COVID-19. The new award expands the scope of SAB’s existing DiversitAb™ Rapid Response Antibody Program contract with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (CBRND), Joint Project Lead CBRND Enabling Biotechnologies (JPL-CBRND-EB).\n\nSAB has announced four awards currently totaling more than $200 million since March of 2020, including funding from the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA).\n\n\"We appreciate the federal government’s expanded support for the further development of SAB-185, our therapeutic candidate with demonstrated ability to neutralize current and emerging variants of concern in multiple SARS-CoV-2 models,” said Eddie J. Sullivan, PhD, co-founder, president and CEO of SAB Biotherapeutics.\n\nDr. Sullivan continued, “The U.S. government has been a tremendous partner in leveraging our novel approach and unique capabilities to help establish and scale our Rapid Response Program that enabled us to accelerate the development and production of SAB-185, a fully human polyclonal antibody therapeutic produced without the need for human donors. Our diverse and highly potent polyclonal antibodies are well-suited for treating rapidly mutating pathogens such as...